Ozempic and Gastroparesis: What Florida Patients Should Know

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Education to Specific Product Exposure

If you're experiencing persistent nausea, vomiting, or abdominal pain after taking Ozempic, you may be wondering if the medication could be the cause. These symptoms overlap with gastroparesis, a condition where the stomach empties slowly, and have been documented in case reports and adverse event databases. Decades of pharmacovigilance research have established a framework for evaluating such post-market safety signals. This page reviews the published evidence, FDA labeling context, and key follow-up questions for patients in Florida.

Bridging to Ozempic and Gastroparesis

This general framework now narrows to a specific medication: Ozempic (semaglutide), a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes mellitus. Its pharmacological action includes slowing gastric emptying, which is a known mechanism that can contribute to gastrointestinal adverse effects. Gastroparesis is a condition characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, abdominal pain, and early satiety. The clinical presentation of gastroparesis overlaps significantly with the gastrointestinal adverse reactions reported in Ozempic clinical trials. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo. Specifically, nausea was reported in 15.8% of patients on Ozempic 0.5 mg and 20.3% on Ozempic 1 mg, compared to 6.1% on placebo. Vomiting occurred in 5.0% and 9.2% of patients on the 0.5 mg and 1 mg doses, respectively, versus 2.3% on placebo. Diarrhea was reported in 8.5% and 8.8% of patients on the two doses, compared to 1.9% on placebo. Abdominal pain occurred in 7.3% and 5.7% of patients on Ozempic, versus 4.6% on placebo. Constipation was reported in 5.0% and 3.1% of patients on Ozempic, compared to 1.5% on placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data indicate a dose-dependent increase in gastrointestinal adverse events, with higher rates at the 1 mg dose compared to 0.5 mg. The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial comparing Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving the 2 mg dose (34.0%) versus the 1 mg dose (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). This further supports a dose-response relationship.

Mechanistic Evidence and Risk Context

Additional gastrointestinal adverse reactions reported at frequencies less than 5% include dyspepsia (3.5% at 0.5 mg, 2.7% at 1 mg), eructation (2.7% at 0.5 mg, 1.1% at 1 mg), flatulence (0.4% at 0.5 mg, 1.5% at 1 mg), gastroesophageal reflux disease (1.9% at 0.5 mg, 1.5% at 1 mg), and gastritis (0.8% at 0.5 mg, 0.4% at 1 mg) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These events, while less common, are consistent with the spectrum of symptoms seen in gastroparesis. The mechanistic pathway linking Ozempic to gastroparesis involves the drug's effect on GLP-1 receptors in the gastrointestinal tract. GLP-1 receptor agonists slow gastric emptying by inhibiting antral contractions and stimulating pyloric tone, which can lead to delayed gastric emptying and symptoms of gastroparesis. This pharmacological effect is well-documented and is considered a class effect of GLP-1 receptor agonists. Regarding the adequacy of warnings, the prescribing information for Ozempic includes a section on gastrointestinal adverse reactions, noting that these events are more common during dose escalation and can lead to discontinuation. However, the label does not explicitly mention gastroparesis as a potential adverse reaction. The reported events such as nausea, vomiting, abdominal pain, and dyspepsia are listed, but the specific diagnosis of gastroparesis is not addressed. This may be relevant for patients who develop persistent or severe symptoms that meet clinical criteria for gastroparesis.

Legal Considerations for Florida Patients

For affected patients in Florida, attorney-related considerations include the statute of limitations for product liability claims. In Florida, the statute of limitations for personal injury claims, including those related to defective drugs, is generally four years from the date the injury was discovered or should have been discovered with reasonable diligence. For wrongful death claims, the statute is two years from the date of death. Patients who have developed gastroparesis after using Ozempic should be aware of these time limits and consult with an attorney promptly to preserve their legal rights. The timeline between exposure to Ozempic and documented harm is variable. Gastrointestinal symptoms often begin during dose escalation, which typically occurs over the first few weeks of treatment. However, some patients may develop symptoms after months of use. The clinical trials reported that the majority of nausea, vomiting, and diarrhea occurred during dose escalation, but persistent symptoms can lead to a diagnosis of gastroparesis after further evaluation. Patients who experience severe or prolonged gastrointestinal symptoms should seek medical evaluation to determine if gastroparesis is present and to document the temporal relationship with Ozempic use. In summary, the evidence from clinical trials demonstrates a clear association between Ozempic use and gastrointestinal adverse reactions that overlap with the clinical presentation of gastroparesis. The pharmacological mechanism of delayed gastric emptying supports this link. Patients in Florida who have developed gastroparesis after using Ozempic should be aware of the statute of limitations and consider legal consultation to evaluate their options.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic-related gastroparesis claims in Florida?

In Florida, the statute of limitations for personal injury claims, including product liability for defective drugs, is generally four years from the date the injury was discovered or should have been discovered. For wrongful death claims, the limit is two years from the date of death. It is important to consult an attorney promptly to ensure your claim is filed within these timeframes.

Does Ozempic cause gastroparesis?

Ozempic (semaglutide) is a GLP-1 receptor agonist that slows gastric emptying, which can lead to symptoms consistent with gastroparesis such as nausea, vomiting, abdominal pain, and early satiety. Clinical trials have reported higher rates of gastrointestinal adverse events in Ozempic users compared to placebo, and the prescribing information does not explicitly list gastroparesis as a potential adverse reaction. Patients experiencing persistent symptoms should seek medical evaluation.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Ozempic Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.